MLD and BML (Japan) announce distribution agreement for PanaSee™ pancreatic cancer screening test kits.

December 17, 2019. Saskatoon SK. Canada. Med-Life Discoveries (MLD) is excited to announce a distribution agreement with BML, a clinical diagnostics lab in Japan, for the PanaSee™ (PC-594) Test Kit intended for identifying increased risk of pancreatic cancer.

The PC-594 Test Kit measures a specific fatty acid in the blood that was discovered and patented by Dr. Shawn Ritchie, CEO and Chief Scientific Officer of MLD, as a risk factor for pancreatic cancer. The PC-594 Test Kit processes 90 patient samples per kit and can be run on any conventional triple-quadrupole mass spectrometer. It contains stable-isotope labelled internal and external standards along with a detailed instructional insert that produces a fully quantitative output. The test is manufactured to very high ISO13485 standards and is fully validated to the FDA’s Bioanalytical Method Validation Guidance for Industry. MLD recently completed on-site verification of the PC-594 test kit’s performance at BML as part of its customer support program.

Dr. Ritchie states, “We are thrilled to have BML now offering its customers the PanaSee™ test for pancreatic cancer risk-based screening. There is currently no simple and effective way to screen for pancreatic cancer risk, and by identifying subjects with a positive PanaSee™ test, it allows those individuals and their doctors to more diligently manage their risk. BML has been offering its customers our colon cancer screening test, Cologic™, for many years. Bringing PanaSee™ on board now puts BML and MLD at the forefront of gastrointestinal-based screening in Japan.”

Dr. Kondo, the president of BML stated, “ I am very pleased to offer PanaSee to the Japanese market.  Pancreatic cancer is a difficult cancer to detect at early stage and the use of PanaSee in the health checkup setting will contribute to the awareness towards early detection of pancreatic cancer. ”   

MLD is a life sciences company dedicated to the early detection and prevention of chronic disease. The company is based out of Saskatoon, SK, Canada and works with collaborators and partners world-wide. MLD’s current products include the GTA-446 Test Kit (Cologic™) for the detection of CRC risk in a blood sample, and the PC-594 Test Kit (PanaSee™) for the detection of pancreatic cancer risk. MLD is also advancing plasmalogen precursor compounds for the treatment of Rhizomelic Chondrodysplasia Punctata (RCDP), Alzheimer’s disease, Levadopa-induced dyskinesias in Parkinson’s disease, and Multiple Sclerosis. For more information see med-life.ca.

BML is a large biomedical testing laboratory in Japan committed to contributing to the creation of a richly cultured society by improving medical services and health through modern technologies, systems, and service networks based on extensive clinical laboratory experience. For more information see bml.co.jp

PanaSee™ and Cologic™ are intended for research use only.